1	Specific Dynamic Variations in the Peripheral Blood Lymphocyte Subsets in
2	COVID-19 and Severe Influenza A Patients: A Retrospective Observational
3	Study
4	Running title: Change of Lymphocyte in COVID-19 and Influenza A Patients
5	
6	Fang Qian <sup>1#</sup> , Guiju Gao <sup>1#</sup> , Yangzi Song <sup>1#</sup> , Yanli Xu <sup>1#</sup> , Aibin Wang <sup>1</sup> , Sa Wang <sup>1</sup> , Yiwei,
7	Hao <sup>4</sup> , Meiling Chen <sup>4</sup> , Xiaoyang Ma <sup>3</sup> , Tianwei Zhao <sup>1</sup> , Xiaodi Guo <sup>2</sup> , Zhihai Chen <sup>1</sup> *,
8	Fujie Zhang <sup>1</sup> *
9	1. Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital
10	Medical University
11	2. Department of Oncology, Beijing Ditan Hospital, Capital Medical University
12	3. Department of Neurology, Beijing Ditan Hospital, Capital Medical University
13	4. Department of Medical Records and Statistics, Beijing Ditan Hospital, Capital
14	Medical University
15	#: These authors contributed equally to this work
16	
17	*: Corresponding Author
18	Fujie Zhang MD.& PhD. Director and Professor of Medicine Clinical and Research
19	Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical
20	University.No.8, Jing shun Dong jie, Chaoyang District Beijing 100015, China
21	treatment@chinaaids.cn
22	Tel: 86-13001953958

## 23 Zhihai Chen

- 24 Professor of Medicine Clinical and Research Center of Infectious Diseases, Beijing
- 25 Ditan Hospital, Capital Medical University, No.8 Jing shun Dong jie, Chaoyang
- 26 District Beijing 100015, China
- 27 Email: chenzhihai0001@126.com
- 28 Tel: 86-13501340403

## 45 Abstract:

#### 46 **Background**:

Both COVID-19 and influenza A contribute to increased mortality among the elderly and those with existing comorbidities. Changes in the underlying immune mechanisms determine patient prognosis. This study aimed to analyze the role of lymphocyte subsets in the immunopathogenesis of COVID-19 and severe influenza A, and examined the clinical significance of their alterations in the prognosis and recovery duration.

53 Methods:

By retrospectively reviewing of patients in four groups (healthy controls, severe influenza A, non-severe COVID-19 and severe COVID-19) who were admitted to Ditan hospital between 2018 to 2020, we performed flow cytometric analysis and compared the absolute counts of leukocytes, lymphocytes, and lymphocyte subsets of the patients at different time points (weeks 1- 4).

## 59 **Results:**

60 We reviewed the patients' data of 110 healthy blood 80 donors, Non-severe-COVID-19, 19 Severe-COVID-19 and 43 severe influenza A. We found 61 total lymphocytes (0.93  $\times 10^{9}$ /L, 0.84  $\times 10^{9}$ /L vs 1.78  $\times 10^{9}$ /L, P < 0.0001) and 62 63 lymphocyte subsets (T cells, CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets) of both severe patients to 64 be significantly lower than those of healthy donors at early infection stages. Further, 65 significant dynamic variations were observed at different time points (weeks 1–4).

66 **Conclusions:** 

- 67 Our study indicates lymphopenia to be associated with disease severity and suggests
- the plausible role of lymphocyte subsets in disease progression, which in turn affects
- 69 prognosis and recovery duration in patients with severe COVID-19 and influenza A.
- 70
- 71 Key words: Coronavirus disease-19 (COVID-19); Severe influenza A; Lymphocyte;
- 72 T cells subsets.
- 73

## 74 Background

75	Since the time the World Health Organization (WHO) declared the infection caused
76	by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus
77	Disease 2019 (COVID-19), a global pandemic, has seriously threatened to global
78	public health and is still expanding. The clinical manifestations of COVID-19 can be
79	mild or severe, which the incidence of mortality is higher among the elderly and
80	among those with pre-existing comorbidities, including hypertension, cardiovascular
81	and cerebrovascular disease, and diabetes, similar to influenza.[1] In addition, their
82	modes of transmission are by contact, droplets, or fomites.[2,3] While relatively little
83	is known about the immunopathological aspects of SARS-CoV-2 virus, there exists
84	vast literature on the possible underlying mechanisms of disease pathogenesis of
85	Influenza A virus.

As previous studies demonstrated that infection of humans with influenza A virus leads to an induction of apoptosis of a portion of CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, and CD19<sup>+</sup> lymphocytes, thus resulting in a severe transient leukopenia, and that lymphocyte apoptosis, which represents a part of an overall beneficial immune response could be a possible mechanism of disease pathogenesis.[4,5]

Although the precise immunopathogenesis of COVID-19 is unknown, genome studies and standard blood investigations suggest involvement of the immune system. Previous studies have shown that severe leukopenia and lymphopenia occur during early stages of infection and subsequently become less prominent as the disease progresses in patients with severe COVID-19.[6,7]Furthermore, as

96 lymphopenia developed in severe COVID-19 cases, it was shown to be a predictor of prognosis and a reliable indicator of disease severity and hospitalization 97 98 in COVID-19 patients.[8] However, data on kinetic alterations in lymphocytes after COVID-19 infection are sparse. To the best of our knowledge, there are no 99 comparative studies focusing on the dynamic variations in lymphocyte subsets of 100 101 patients with influenza A and SARS-Cov-2 infections. Whether changes in the underlying immune mechanisms determine patient prognosis and recovery in 102 103 COVID-19 remains unclear. Therefore, in view of the above, in this retrospective 104 study, we analyzed the role of lymphocytes and lymphocyte subsets in the immunopathogenesis of COVID-19 and severe influenza A, to provide us with 105 106 valuable insights for better understanding of the underlying immune mechanisms 107 following SARS-Cov-2 and severe influenza A infections.

108

109 Methods

## 110 Study design and participants

We retrospectively reviewed the clinical data of all patients who were confirmed to have COVID-19 and were admitted to the Beijing Ditan Hospital from January 20, 2020 to March 17, 2020. In addition, all patients with severe influenza A who were admitted to Ditan hospital between 2018 to 2020 were recruited for this study. A group of healthy blood donors who were previously recruited in 2018 were used to provide data for the healthy controls in this study. This study was approved by the Ethics Committee of Beijing Ditan Hospital (No. 202000601). The need for

118 individual consent was waived because of the retrospective nature of the study.

119	The patients with COVID-19 were divided into non-severe and severe pneumonia
120	groups according to the Diagnosis and Treatment Protocols for Patients with
121	COVID-19 (Trial Version 7, Revised).[9]The diagnostic criteria for patients with
122	non-severe COVID-19 included: (1) Epidemiological history, (2) Fever or other
123	respiratory symptoms, (3) Typical computed tomography (CT) image abnormities of
124	viral pneumonia, and (4) Positive result of reverse transcription-polymerase chain
125	reaction (RT-PCR) for SARS-CoV-2 Ribonucleic acid (RNA), while those with
126	severe COVID-19 additionally met at least one of the following conditions: (1)
127	Shortness of breath or dyspnea, with a respiratory rate of 30 times/min, (2) Oxygen
128	saturation (resting state) 93%, or (3) PaO2 / FiO2 300 mmHg.
129	Samples of patients with COVID-19 that were SARS-CoV-2 positive based on nucleic
130	acid detection and showed the presence of lymphocyte subset population for
131	approximately four weeks after onset, where lymphocyte subset analyses were
132	performed at least twice within the four weeks duration, were included in this study.
133	However, those samples that were SARS-CoV-2 nucleic acid positive and either

lacked or showed the presence of only one lymphocyte subset population forapproximately four weeks after onset were not considered for this study.

Patients with severe influenza were diagnosed based on Influenza: Diagnosis and
Treatment (2019).[10]The diagnostic criteria were as follows: sustained high fever>3
days accompanied by severe cough, coughing up sputum or bloody sputum, or chest
pain; rapid breathing rate, respiratory distress, and cyanosis of lips; change in

140	consciousness such as unresponsiveness, drowsiness, restlessness, or convulsions;
141	Severe vomiting, diarrhea, dehydration; presence of symptoms associated with
142	pneumonia; exacerbation of pre-existing conditions and/or diseases; other clinical
143	conditions requiring hospitalization. Patients with severe influenza A admitted to our
144	hospital who met the above criteria were included in this study. Patients were
145	excluded if an alternative diagnosis, such as the presence of influenza B,
146	parainfluenza, respiratory syncytial virus, adenovirus, mycoplasma, chlamydia,
147	legionella was determined.
148	Healthy controls who tested negative for human immunodeficiency virus (HIV)

infection, hepatitis viral infections, systemic infections, connective tissue diseases,cancer, or any other abnormal tumor markers were considered.

Patients in four groups (non-severe COVID-19 and severe COVID-19, severe
influenza A, and healthy controls) excluded minors younger than eighteen years old
and pregnant women.

## 154 Data collection

The information related to age, gender, onset of symptoms, medical history of pre-existing comorbidities (hypertension, diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular disease, chronic kidney disease, and/or autoimmune disease), severity assessment on admission, laboratory findings, and treatment regimen for each patient was extracted from electronic medical records.

## 160 Laboratory confirmation

161 Laboratory confirmation tests for COVID-19 were performed by Beijing Center for

162	Disease Control and Prevention (CDC) and Beijing Ditan Hospital. Throat swab
163	and/or sputum specimens were collected from all patients at admission and were
164	tested the same day. Patients were confirmed to be positive for SARS-CoV-2 nucleic
165	acid by real-time fluorescent reverse transcriptase-polymerase chain reaction assay,
166	according to the WHO interim guidance for COVID-19.[11]
167	The diagnosis of severe influenza virus infection was confirmed by RT-PCR of
168	nasopharyngeal swabs.[10]
169	Flow cytometric analyses
170	To explore the cellular immune response of patients with severe and non-severe
171	COVID-19 and severe influenza A, peripheral blood samples (2mL each) were
172	collected from healthy controls and all patients at week 1 (0-7 days), week 2 (8-14
173	days), week 3 (15-21 days), and week 4 (22-28 days) from the initial onset of
174	symptoms, for analyses of complete blood cell counts and cell counts of lymphocyte
175	subsets (CD4 <sup>+</sup> T cell, CD8 <sup>+</sup> T cell, B cell, and natural killer (NK) cell counts [cells/ $\mu$ L]
176	and CD4 <sup>+</sup> T/CD8 <sup>+</sup> T ratio). Lymphocyte subsets were detected and counted by BD
177	FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), and the subsets
178	were characterized according to phenotypes of the corresponding CD antigens.
179	For T cell subset identification and counting, a Four ColorHuman
180	CD3/CD8/CD45/CD4 Flow Kit was employed, according to manufacturer's
181	instructions. Briefly, 50 $\mu L$ of the isolated peripheral blood mononuclear cells was
182	incubated directly with the Four Color reagent consisting of a combination of
183	RPE-Cy5.5 conjugated CD3 (Mouse IgG1), APC conjugated CD8 (Mouse IgG1),

184 RPE conjugated CD45 (Mouse IgG2a), and fluorescein isothiocyanate 185 (FITC)-conjugated CD4 (mouse IgG1) monoclonal antibodies for 15 min at 4°C in 186 absolute counting tubes. Subsequently, 450  $\mu$ L of red blood cell lysing solution (1xBD 187 lysing solution) was added to the tubes before performing the flow cytometric 188 analysis. The samples were then incubated at room temperature for 5 min prior to 189 detection by BD FACS Calibur flow cytometer. Data were obtained and analyzed 190 automatically by the MultiSET software.

## 191 Statistical analyses

192 All analyses were performed using SPSS statistical software (version 26.0, IBM, 193 Armonk, NY, USA). Categorical data are expressed in frequency or percentage, and 194 statistical significance was determined by  $\chi^2$  or Fisher's exact test. Nonparametric 195 variables are expressed as median with interquartile range (IQR). For continuous data, 196 Mann-Whitney U test or Kruskal Wallis test was performed to compare variables 197 between different groups and determine the statistical significance. In all analyses, P 198 < 0.05 was statistically significant. The dynamic changes of different subsets of 199 lymphocytes at different time periods are represented by boxplots.

200

#### 201 **Results**

202 Demographic and clinical characteristics of patients with COVID-19 and severe 203 influenza A

In our study, we retrospectively reviewed the clinical data of 110 healthy blood donors (healthy controls), 99 patients with COVID-19 and 43 patients with severe

206	influenza A. The group with healthy controls (HC) comprised of 53 males (48%) and
207	57 females (52%). Among the 99 patients with COVID-19, 56 were men (56.6%) and
208	43 were women (43.4%).All the COVID-19 patients were divided into two groups,
209	according to the abovementioned diagnostic criteria, and there were 80 non-severe
210	cases (80.8%) and 19 severe cases (19.2%; Table 1). The median age of patients with
211	non-severe and severe COVID-19 was 37 (30-49) years and 67 (53-74) years,
212	respectively. The severe patient group had a higher age than the non-severe
213	COVID-19 group. The median durations of hospitalization of patients with
214	non-severe and severe COVID-19 were 4 (2, 7) and 5 (4.5, 10) days, respectively.
215	All the patients with severe COVID-19 (n =19, 100%) presented with fever, cough,
216	and dyspnea. On the contrary, only a few patients with non-severe COVID-19 had
217	fever (n = 58, 73%) and cough (n = 38, 48%). Notably, none of them had dyspnea.
217 218	fever (n = 58, 73%) and cough (n= 38, 48%). Notably, none of them had dyspnea. A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic
217 218 219	fever (n = 58, 73%) and cough (n= 38, 48%). Notably, none of them had dyspnea. A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic medical conditions, including diabetes (8 [11%]), hypertension (24 [32.9%]), COPD
217 218 219 220	fever (n = 58, 73%) and cough (n= 38, 48%). Notably, none of them had dyspnea. A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic medical conditions, including diabetes (8 [11%]), hypertension (24 [32.9%]), COPD (2 [2.8%]), cardiovascular disease (2 [2.8%]), renal disease (1 [1.4%]), and
217 218 219 220 221	fever (n = 58, 73%) and cough (n= 38, 48%). Notably, none of them had dyspnea. A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic medical conditions, including diabetes (8 [11%]), hypertension (24 [32.9%]), COPD (2 [2.8%]), cardiovascular disease (2 [2.8%]), renal disease (1 [1.4%]), and autoimmune disorders (5 [6.9%]). Specifically, 19 patients (24%) with non-severe
217 218 219 220 221 222	fever (n = 58, 73%) and cough (n= 38, 48%). Notably, none of them had dyspnea. A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic medical conditions, including diabetes (8 [11%]), hypertension (24 [32.9%]), COPD (2 [2.8%]), cardiovascular disease (2 [2.8%]), renal disease (1 [1.4%]), and autoimmune disorders (5 [6.9%]). Specifically, 19 patients (24%) with non-severe COVID-19 and 12 patients (63%) with severe COVID-19 presented with one or more
<ul> <li>217</li> <li>218</li> <li>219</li> <li>220</li> <li>221</li> <li>222</li> <li>222</li> <li>223</li> </ul>	fever (n = 58, 73%) and cough (n= 38, 48%). Notably, none of them had dyspnea. A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic medical conditions, including diabetes (8 [11%]), hypertension (24 [32.9%]), COPD (2 [2.8%]), cardiovascular disease (2 [2.8%]), renal disease (1 [1.4%]), and autoimmune disorders (5 [6.9%]). Specifically, 19 patients (24%) with non-severe COVID-19 and 12 patients (63%) with severe COVID-19 presented with one or more of the pre-existing chronic medical conditions (Table 1). One patient in the severe
217 218 219 220 221 222 223 223 224	fever (n = 58, 73%) and cough (n= 38, 48%). Notably, none of them had dyspnea. A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic medical conditions, including diabetes (8 [11%]), hypertension (24 [32.9%]), COPD (2 [2.8%]), cardiovascular disease (2 [2.8%]), renal disease (1 [1.4%]), and autoimmune disorders (5 [6.9%]). Specifically, 19 patients (24%) with non-severe COVID-19 and 12 patients (63%) with severe COVID-19 presented with one or more of the pre-existing chronic medical conditions (Table 1). One patient in the severe COVID-19 group died on day 28 after the onset of the disease.
<ul> <li>217</li> <li>218</li> <li>219</li> <li>220</li> <li>221</li> <li>222</li> <li>223</li> <li>224</li> <li>225</li> </ul>	fever (n = 58, 73%) and cough (n= 38, 48%). Notably, none of them had dyspnea. A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic medical conditions, including diabetes (8 [11%]), hypertension (24 [32.9%]), COPD (2 [2.8%]), cardiovascular disease (2 [2.8%]), renal disease (1 [1.4%]), and autoimmune disorders (5 [6.9%]). Specifically, 19 patients (24%) with non-severe COVID-19 and 12 patients (63%) with severe COVID-19 presented with one or more of the pre-existing chronic medical conditions (Table 1). One patient in the severe COVID-19 group died on day 28 after the onset of the disease. Similar to the group with severe COVID-19, the median age of patients with severe
<ul> <li>217</li> <li>218</li> <li>219</li> <li>220</li> <li>221</li> <li>222</li> <li>223</li> <li>224</li> <li>225</li> <li>226</li> </ul>	fever (n = 58, 73%) and cough (n= 38, 48%). Notably, none of them had dyspnea. A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic medical conditions, including diabetes (8 [11%]), hypertension (24 [32.9%]), COPD (2 [2.8%]), cardiovascular disease (2 [2.8%]), renal disease (1 [1.4%]), and autoimmune disorders (5 [6.9%]). Specifically, 19 patients (24%) with non-severe COVID-19 and 12 patients (63%) with severe COVID-19 presented with one or more of the pre-existing chronic medical conditions (Table 1). One patient in the severe COVID-19 group died on day 28 after the onset of the disease. Similar to the group with severe COVID-19, the median age of patients with severe influenza A infection was higher (70 years) than that of those of healthy controls (45

227 years). Notably, the difference in age was found to be statistically significant (P <

0.05) between the groups. All patients with severe influenza A infection (n = 43, 100%) presented with fever and cough. However, only 33 patients (77%) had dyspnea.
Out of 43 patients with severe influenza A, 4 (9%) died and 39 (91%) survived (Table 1).

#### 232 Variations in leukocyte populations in COVID-19 and severe influenza A

233 We analyzed different variations in leukocyte subpopulations of patients with non-severe and severe COVID-19 and severe influenza A during the first week of 234 235 illness. The absolute counts of total white blood cells (WBCs) of patients with non-severe  $(5.34 \times 10^{9}/L, P < 0.001)$  and severe COVID-19  $(3.92 \times 10^{9}/L, P < 0.0001)$ 236 were significantly lower than those of the healthy donors (6.01  $\times 10^{9}$ /L; Table 2). 237 238 Moreover, a statistically significant difference was observed between WBC counts of 239 patients with non-severe and that of those with severe COVID-19 (P = 0.049). Further, 240 there was a significant difference between the WBC counts of patients with severe 241 influenza A and those of patients with severe COVID-19 (P = 0.027).

Expectedly, the absolute counts of lymphocytes in healthy donors  $(1.78 \times 10^9/L)$  were significantly higher than those of patients with non-severe COVID-19  $(1.51 \times 10^9/L, P$ = 0.027), severe COVID-19  $(0.93 \times 10^9/L, P < 0.0001)$ , and severe influenza A (0.84  $\times 10^9/L, P < 0.0001$ ) during the first week of illness (Table 2). Further, there was a significant difference in the absolute lymphocyte counts of patients with non-severe and severe COVID-19 (P < 0.0001).

248 Distinct alterations in peripheral lymphocyte subsets in COVID-19 and severe
249 influenza A

250	To further determine variations in different lymphocyte subsets in peripheral blood
251	samples of patients with non-severe COVID-19, severe COVID-19, and severe
252	influenza A during the first week of illness, we performed flow cytometric analysis to
253	enumerate total T cell population, $CD4^+$ and $CD8^+$ T cell subsets, B cells and NK cells.
254	Similar to the findings of the absolute counts of total lymphocytes, patients with
255	severe COVID-19 and severe influenza A had a significantly lower number of total T
256	cells ( $P = 0.001$ and $P < 0.0001$ , respectively), CD4 <sup>+</sup> T cells ( $P = 0.001$ and $P$
257	<0.0001, respectively), and CD8 <sup>+</sup> T cells ( $P = 0.001$ and $P < 0.0001$ , respectively)
258	than healthy controls.
259	Notably, there was a significant difference between the $CD8^+$ T cell subset ( $P = 0.036$ )
260	counts of patients with non-severe COVID-19 and those of healthy donors. The
261	differences in the total T cell population ( $P < 0.0001$ ), CD4 <sup>+</sup> T cell subset ( $P = 0.001$ ),
262	and $CD8^+$ T cell subset ( $P = 0.001$ ) of patients with non-severe and severe COVID-19
263	were statistically significant (Table 2).
264	In addition, the median of $CD4^+/CD8^+$ ratio in non-severe COVID-19, severe
265	COVID-19 and severe influenza group showed no different compared to HCs ( $P = 0$ .
266	242, $P = 0.221$ and $P = 0.651$ , respectively). And at the same time, the median NK cells
267	of non-severe and severe COVID-19 patients showed no difference compared to HCs
268	( $P = 0.514$ and $P = 0.355$ , respectively). There was no significant difference in B cells
269	between the severe and non-severe COVID-19 groups ( $P = 0.093$ ). (Table 2)
270	Dynamic changes in leukocyte and lymphocyte subset counts with disease
271	progression and assessment of severity

As shown in Table 2, total WBCs, the absolute lymphocytes, total T cells, CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets in the peripheral blood samples of all patients were found to be lower than those of healthy donors at the time of disease onset. To further determine significant changes in the immune cell subsets of patients with non-severe COVID-19, severe COVID-19, and severe influenza A, with disease evolution, we compared the absolute counts of leukocytes, total lymphocytes, and lymphocyte subsets of the three patient groups at weeks 1, 2, 3, and 4.

279 Unlike other groups, in patients with severe COVID-19, leukocyte counts gradually 280 increased from week 1 to week 4, despite being lower than the normal. Notably, the 281 variations in leukocyte counts were found to be statistically significant. (W1-W2: P =282 0.013, W1-W3: P = 0.003, W1-W4: P = 0.001). A similar trend was observed with 283 total lymphocyte count, which sharply increased at week 3, showing a significant 284 difference compared to those at weeks 1 and 2(W1-W3: P = 0.013, W1-W4: P 285 =0.002, W2-W3: P = 0.001) (Fig. 1 A, B).On the other hand, a significant and a 286 drastic increase was noted in the cell counts of total T cell and CD4<sup>+</sup> T cell subset at 287 week 4 when compared with those of weeks 1 and 2. (W1-W4: P = 0.034, W2-W4: P288 =0.003; W1-W4: P = 0.020, W2-W4: P = 0.001)(Fig.1 C- E).

Consistent with the findings of patients with severe COVID-19, the leukocyte counts of patients with non-severe COVID-19 were significantly higher in week 3 than those of week 1 and week 2 (W1-W3: P = 0.005, W2-W3: P = 0.044). A similar tendency was seen with lymphocyte count, which showed a sharp significant increase at week 3 compared with that seen at week 1 (W1-W3: P = 0.004). Interestingly, a significant

294	change in total T cell count was observed at week 3, suggesting a marked increase in
295	total T cell population when compared with that observed at week 2 (W2-W3: $P =$
296	0.045)(Fig. 1 A-C). The differences in the absolute counts of total lymphocytes, total T
297	cells, $CD4^+$ and $CD8^+$ T cell subsets were found to be significant between the severe
298	and non-severe COVID-19 groups at all time points (weeks 1 through 4), although
299	they were visibly lower than those of healthy controls (Fig. 1 B-E). When compared
300	with healthy controls, no significant changes were seen in B cell populations and
301	$CD4^+/CD8^+$ ratios of patients with severe and non-severe COVID-19 during the four
302	weeks following the infection (Fig. 1 F, H). Interestingly, the NK cell counts of patients
303	with severe and non-severe COVID-19 gradually increased from weeks 2 to 4. These changes
304	were found to be statistically significant (W2-W4: $P = 0.011$ and $P = 0.042$ , respectively) (Fig.
305	1 G).On the contrary, in patients with severe influenza A infection, significant changes were
306	only evident in the cell counts of total T cells, $CD4^+$ and $CD8^+$ T cell subsets (W1-W2: $P =$
307	0.003, $P = 0.006$ , and $P = 0.030$ , respectively) ( <b>Fig.1 C-E</b> ).

308

## 309 Discussion

In this study, we aimed to analyze the role of lymphocyte subsets in the immunopathogenesis of COVID-19 and severe influenza A, and examined the clinical significance of their alterations, especially in determining the prognosis and recovery duration. Our analyses revealed significant dynamic variations in total lymphocytes and lymphocyte subsets, which get activated in the early stages of COVID-19 and severe influenza A infections, and further demonstrated that severe immune injury

tended to be more prominent in patients with severe form of the disease. The recovery
rate of patients with severe COVID-19 was comparatively longer than those who
received immediate antiviral treatment for severe influenza A and those with
non-severe COVID-19.

320 We retrospectively reviewed the clinical data of 99 patients who were confirmed to 321 have COVID-19, 43 patients with severe influenza A and 110 healthy blood donors 322 who were previously recruited in 2018. All the patients with COVID-19 were divided 323 into two groups, according to the abovementioned diagnostic criteria, including 80 324 non-severe cases (80.8%) and 19 severe cases (19.2%). Several reports and studies 325 have clearly indicated that older or elderly people are more prone to COVID-19 as 326 their immune systems are likely to get overwhelmed by infections due to their 327 advanced age. Similarly, the elderly who are 65 years or older are particularly at risk 328 for influenza infection, hospitalization, and death due to influenza-related 329 complications, such as pneumonia.[12] In our study, the median age of patients with 330 non-severe COVID-19 was 37 years, while that of those with severe COVID-19 was 331 67 years. Consistent with the previous studies, our data indicate that the ages of the 332 severe patient group are higher than those of the non-severe COVID-19 group. 333 Further, our study showed that the median age of patients with severe influenza A 334 infection was higher (70 years) than that of those with non-severe COVID-19 (37 335 years) and healthy controls (45 years). Notably, this difference in age was found to be 336 statistically significant (P < 0.05) among the groups, which suggests that the elderly 337 people represent a large at-risk population.

338	The WHO-China joint report on COVID-19 provided a comprehensive
339	symptomatology of COVID-19 ( $n = 55,924$ )[13]. A previous study showed that
340	patients with COVID-19 present with pyrexia in 85% of cases during their illness
341	course, but only 45% are febrile on early presentation. In addition to cough (67.7%)
342	and sputum (33.4%), respiratory symptoms, such as dyspnea, sore throat, and nasal
343	congestion were reported to be present in 18.6%, 13.9%, and 4.8% of cases,
344	respectively. Both COVID-19 and influenza present with common clinical
345	manifestations including fever, cough, rhinitis, sore throat, headache, dyspnea, and
346	myalgia. [7,14,15]In our study, all the patients with severe COVID-19 presented with
347	fever, cough, and dyspnea, whereas only 73% and 48% of patients with non-severe
348	COVID-19 had fever and cough, respectively. Similar to the severe COVID-19 group,
349	all patients with severe influenza A infection presented with fever and cough.
350	However, only 77% of the patients had dyspnea. These clinical manifestations of
351	COVID-19 and influenza infections were consistent with other studies. As previously
352	reported the mortality rate also increases in patients with additional comorbidities.[3]
353	Specifically, 63% and 84% patients with severe COVID-19 and severe influenza A,
354	respectively, presented with one or more pre-existing chronic medical conditions.
355	While the mortality rate was 5% due to severe COVID-19, it was even higher (9%)
356	for severe influenza A.

Lymphocytes and their subsets play a crucial role in maintaining immune homeostasis and
inflammatory response in the host. As in case of immune disorders and other infections, a
viral infection impairs the host's immune defenses and results in decreased levels of

360	lymphocytes and their subsets.[16,17] Lymphocyte subsets, namely CD4 <sup>+</sup> T cells, CD8 <sup>+</sup> T
361	cells, B cells, and NK cells are primarily involved in the humoral and cytotoxic immunity
362	against viral infection. Therefore, this necessitates the need to understand the mechanism of
363	reduced blood lymphocyte levels and characterize the dynamic alterations of lymphocyte
364	subsets to provide novel insights for an effective treatment and prognosis of COVID-19.As
365	lymphopenia is frequently observed during the initial stages of respiratory viral
366	infection.[3,18] We identified and analyzed different variations in leukocytes, lymphocytes,
367	and lymphocyte subsets in patients with non-severe and severe COVID-19 and severe
368	influenza A during the first week of illness. Our results showed that the absolute counts of
369	total WBCs and lymphocytes of patients with non-severe (5.34 $\times 10^9$ /L, P < 0.001 and 1.51
370	$\times 10^{9}$ /L, P = 0.027, respectively) and severe COVID-19 (3.92 $\times 10^{9}$ /L, P < 0.0001 and 0.93
371	$\times 10^{9}$ /L, <i>P</i> < 0.0001, respectively) were significantly lower than those of healthy donors (6.01
372	$\times 10^{9}$ /L and 1.78 $\times 10^{9}$ /L, respectively). Further, the total lymphocyte counts of patients with
373	severe influenza A were comparatively lower than those of healthy donors, (0.84 $\times 10^{9}$ /L, P <
374	0.0001). These findings are corroborated by a previous study which hypothesized that the
375	virus might directly infect lymphocytes resulting in their apoptosis, thus leading to causing a
376	sharp decline in total lymphocyte population and subsequent lymphopenia. Moreover,
377	lymphocytes express the coronavirus receptor angiotensin-convertingenzyme 2(ACE-2),
378	and therefore are a direct target for the virus.[19] Another retrospective study suggested that
379	lymphopenia might be one of the predictive factors for progression to respiratory failure
380	during early stages following Middle East Respiratory Syndrome coronavirus
381	(MERS-Cov) infection.[20] Giving further strength to our study, a study by Geng et al.

382	demonstrated the decline in the populations of T lymphocytes and their subsets, after
383	influenza A virus infection, to be positively correlated with prognosis.[21]We further
384	performed flow cytometric analysis to enumerate total T cell population, $CD4^+$ and $CD8^+$ T
385	cell subsets, B cells and NK cells in patients with non-severe COVID-19, severe COVID-19,
386	and severe influenza A to determine significant changes in different lymphocyte subsets
387	during their first week of illness. Our study demonstrated that patients with severe COVID-19
388	and severe influenza A had a significantly lower number of total T cells ( $P = 0.001$ and $P$
389	<0.0001, respectively), CD4 <sup>+</sup> T cell subsets ( $P = 0.001$ and $P < 0.0001$ , respectively), and
390	CD8 <sup>+</sup> T cell subsets ( $P = 0.001$ and $P < 0.0001$ , respectively) than healthy controls. Further,
391	significant differences in total WBCs ( $P = 0.049$ ), total lymphocytes ( $P < 0.0001$ ) total T cell
392	population ( $P < 0.0001$ ), CD4 <sup>+</sup> T cell subsets ( $P = 0.001$ ), and CD8+ T cell subsets ( $P =$
393	0.001) were observed between patients with non-severe and severe COVID-19. Notably, there
394	was a significant reduction in $CD8^+$ T cell subsets ( $P = 0.036$ ) in patients with non-severe
395	COVID-19 compared with healthy controls. This indicates a more obvious change in $CD8^+$ T
396	cell subsets than in other lymphocyte subsets following SARS-CoV-2 infection. Therefore,
397	our results reiterate the fact that CD8+ T cell responses play a major role in antiviral
398	immunity.[22] Taken together, lymphopenia was common in the patients with COVID-19,
399	indicating a significant impairment in the host's immune system following SARS-CoV-2 and
400	influenza A infections. Our findings are in line with other studies which also detected these
401	alterations in patients with pneumonia caused by MERS-CoV and Severe acute respiratory
402	syndrome coronavirus (SARS-CoV).[20, 23] In addition, a significant reduction in both
403	CD4 <sup>+</sup> T cells and CD8+ T cells were specifically observed in patients with severe COVID-19

and severe influenza A. Therefore, this indicates a more severe immune insult in patients with
the severe form of the disease. Consequently, the alteration would be more profound, and
leads to adverse clinical outcome in these patients. Thus, lymphocytes and their subsets,
especially CD8<sup>+</sup> T cells, might be a potential predictor for disease severity and clinical
efficacy in COVID-19.

409 Next, we focused on the dynamics of T lymphocytes and their subsets, which played a 410 vital role in cellular immune responses. We compared the absolute counts of 411 leukocytes, total lymphocytes, and lymphocyte subsets of the non-severe and severe 412 COVID-19 patient groups at weeks 2, 3, and 4 with that of those observed during the 413 initial stages of infection. The total leukocyte, lymphocyte, and T cell counts 414 significantly improved at week 3 in patients with non-severe COVID-19. Lymphocyte 415 also recovered markedly at week 3 in severe COVID-19 patients. However, T cell and 416 CD4<sup>+</sup> T cell subset population significantly increased at week 4 in patients with 417 severe COVID-19. Our results are consistent with a previous study by He et al. that 418 showed a sharp decline (below normal) in the cell counts of CD45<sup>+</sup>, CD3<sup>+</sup> T cell 419 subsets, CD4<sup>+</sup> T cell subsets, and CD8<sup>+</sup> T cell subsets during the first week of 420 SARS-Cov infection; their values further declined during the second week before 421 increasing during the third week and returning to normal by the fifth week. Moreover, 422 CD4<sup>+</sup> T and CD8<sup>+</sup> T cell counts were found to be extremely low in critically ill and 423 deceased patients. [23] Taken together, the alterations in lymphocytes and their subsets 424 gradually improved at later time points in patients with COVID-19. Collectively, our 425 results indicate that the recovery duration of patients with severe COVID-19 is longer

426 than those with the mild form of the disease.

427 Our study results further revealed a noticeable difference in the time taken for the cell 428 counts to improve among the severe and non-severe COVID-19 and the severe 429 influenza groups. The cell counts of total lymphocytes and their subsets recovered 430 only around week 4 in severe COVID-19; the recovery time was almost delayed by a 431 week compared with those having non-severe COVID-19. On the contrary, the cell counts of total lymphocytes and their subsets in patients with severe influenza A 432 433 increased and improved drastically at week2; this rapid recovery rate could be 434 attributed to the early initiation of treatment with the neuraminidase inhibitor, 435 oseltamivir, or peramivir, which interfere with virus release from host cells by 436 blocking the viral nucleic acid function, thus preventing infection of new host 437 cells.[24]

438 NK cells are cytotoxic innate lymphocytes that play an important role in controlling 439 the viral burden. NK cell responses can be specific, and they interact with both innate 440 and adaptive immune cells to coordinate appropriate antiviral responses.[25] Although 441 we observed a reduction in NK cell counts during the initial stages of infection in 442 patients with severe and non-severe COVID-19, their recovery rate (cell counts 443 improved at week 3) showed a similar trend as that of the lymphocytes in both the 444 groups. One plausible reason for this observation could be that the NK cell cross-talk 445 might have got suppressed following the virus attack, which might have further led to 446 impairment of  $CD4^+$  T cell responses and their effects on  $CD8^+$  T cells. This is further supported by a finding from this study which demonstrated a significant reduction in 447

448 CD4<sup>+</sup> T cell subsets, especially in patients with severe COVID-19. Given the role of 449 B cells in adaptive immune response, we did not observe any significant changes in 450 total B cell population in all patients with COVID-19 during the course of illness. 451 This could possibly be attributed to the poor activation of the adaptive immune 452 response against the virus. Moreover, the lack of detectable virus during stage I 453 (asymptomatic incubation period)of the SARS-CoV-2 infection might have failed to 454 elicit protective B cell immunity.[26]Therefore, future research focusing on strategies 455 to enhance the specific adaptive immune responses during the incubation and 456 non-severe stages of the SARS-CoV-2 infection could significantly boost the B cell 457 population, preventing the progression to the stage III severe respiratory symptomatic 458 stage with high viral load. Furthermore, studies identifying specific immune 459 components or functions that limit protective immunity to virus infection are 460 warranted.

Our study has several limitations. This study was retrospective, small single-center study and only included a small sample of 99 patients with COVID-19 admitted to Beijing Ditan Hospital, which may confound the results and potentially introduce selection bias. This may limit the generalizability of the study. In addition, inconsistencies in time periods between illness onset and admission might have led to missing data which could result in observation biases in the dynamic variations in immune cells.

## 468 Conclusions

469 Collectively, our study indicates that lymphopenia might be associated with disease

470	severity and suggests the plausible role of lymphocyte subsets in disease progression,
471	which in turn affects prognosis and recovery duration in patients with severe
472	COVID-19 and influenza A. The dynamic alterations in lymphocytes and their subsets
473	provides valuable insights into the immunopathogenesis of disease progression in
474	COVID-19.
475	
476	
477	
478	
479	
480	
481	
482	
483	
484	
485	
486	
487	
488	
489	
490	
491	

## 492 Abbreviations

- 493 COVID-19: Coronavirus disease-19
- 494 WHO: World Health Organization
- 495 SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
- 496 CT: Computed tomography
- 497 RT-PCR: Reverse transcription-polymerase chain reaction
- 498 RNA Ribonucleic acid
- 499 HIV: human immunodeficiency virus
- 500 COPD: chronic obstructive pulmonary disease
- 501 CDC: Center for Disease Control and Prevention
- 502 NK: natural killer
- 503 IQR: interquartile range
- 504 HC: healthy controls
- 505 WBC: White blood cells
- 506 LY: Lymphocytes
- 507 ACE-2: angiotensin-convertingenzyme 2
- 508 MERS- CoV: Middle East Respiratory Syndrome coronavirus
- 509 SARS-CoV: Severe acute respiratory syndrome coronavirus
- 510
- 511
- 512
- 513

## 514 **Declarations**

## 515 *Ethics approval and consent to participate*

- 516 This study was approved by the Ethics Committee of Beijing Ditan Hospital (No.
- 517 202000601). The need for individual consent was waived because of the retrospective
- 518 nature of the study.

## 519 Consent for publication

520 Not applicable.

## 521 Availability of data and material

- 522 The datasets used and/or analysed during the current study are available from the corr
- 523 esponding author on reasonable request.

### 524 Competing interests

- 525 The authors declare that they have no competing interests.
- 526 Funding
- 527 None.

## 528 Authors' contributions

FZ and ZC were responsible for the study concept and design. They had complete access to all the data in this study and take responsibility for data integrity and accuracy of the data analysis. FQ and YS contributed to the writing of this manuscript. FQ, GG, YX, AW, SW, XM, TZ and XG contributed to the sample acquisition of patients, diagnosis, and treatment. FQ and YS contributed to data collection, data interpretation, and analysis of the results. YH and MC conducted the statistical analyses. All authors reviewed and approved the final manuscript.

## 536 Acknowledgments

537	We acknowledge all health-care workers involved in the diagnosis and treatment of
538	patients in Beijing Ditan Hospital, Capital Medical University.
539	
540	
541	
542	
543	
544	
545	
546	
547	
548	
549	
550	
551	
552	
553	
554	
555	
556	
557	

## 558 **References**

559	1. Fauci AS, Lane HC, Redfield RR. Covid-19 - Navigating the Uncharted. N Engl J
560	Med. 2020;382(13):1268-1269.
561	2. United States Centers for Disease Control and Prevention. Interim guidance on
562	the use of influenza antiviral agents during the 2010-2011 influenza season.
563	http://www.cdc.ov/flu/professionals/antivirals/guidance/summary.html. Accessed 20
564	Mar 2020.
565	3. Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the
565 566	3. Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019
565 566 567	<ol> <li>Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus. 2020;12(4):e7560.</li> </ol>
565 566 567 568	<ol> <li>Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus. 2020;12(4):e7560.</li> <li>Guo X, Chen Y, Li X, Kong H, Yang S, Ye B, et al. Dynamic variations in the</li> </ol>
565 566 567 568 569	<ol> <li>Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus. 2020;12(4):e7560.</li> <li>Guo X, Chen Y, Li X, Kong H, Yang S, Ye B, et al. Dynamic variations in the peripheral blood lymphocyte subgroups of patients with 2009 pandemic H1N1</li> </ol>

- 5. Nichols JE, Niles JA, Roberts NJ, Jr. Human lymphocyte apoptosis after
  exposure to influenza A virus. J Virol. 2001;75(13):5921-5929.
- 573 6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and
- clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
- 575 China: a descriptive study. Lancet. 2020;395(10223):507-513.
- 576 7. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics
- 577 of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
- 578 8. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia
- 579 predicts disease severity of COVID-19: a descriptive and predictive study. Signal
- 580 Transduct Target Ther. 2020;5(1):33.
- 581 9. National Health Commission of the People's Republic of China. Diagnosis and
- 582 Treatment Protocols for Patients with COVID-19 (Trial Version7, Revised).

583 http://www.nhc.gov.cn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5a

- 584 f95.shtml. Accessed 16 July 2020.
- 585 10. National Health Commission of the People's Republic of China. Diagnosis and
- 586 Treatment Protocols for Patients with influenza (Version2019).
- 587 http://www.nhc.gov.cn/yzygj/s7653p/201911/a577415af4e5449cb30ecc6511e369c7.
- shtml. Accessed 16 July 2020.
- 589 11. World Health Orgazation. Clinical management of severe acute respiratory
- infection when novel coronavirus (nCoV) infection is suspected: interim guidance.
- 591 Accessed at https://www.who.int/publications-detail/clinical-management-of-severe-
- 592 acute-respiraory-infection-whennovel-coronavirus-(ncov)-infection-is-suspected.
- 593 Accessed 16 July 2020.
- 594 12. Wilhelm M. Influenza in older patients: a call to action and recent updates for
  595 vaccinations. Am J Manag Care. 2018;24(2 Suppl):S15-S24.
- 596 13. World Health Organization. WHO-China joint mission on coronavirus disease
- 597 2019(COVID-19). Accessed at https://www.who.int/news-room/feature-stories/detail/
- 598 who-china-joint-mission-on-coronavirus-disease-2019. Accessed 28 Mar 2020.
- 599 14. Ozaras R, Cirpin R, Duran A, Duman H, Arslan O, Bakcan Y, et al. Influenza and
- 600 COVID-19 coinfection: Report of six cases and review of the literature. J Med Virol.
- 601 2020.doi: 10.1002/jmv.26125
- 15. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from
- 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet
- 604 Infect Dis. 2020;20(4):425-434.
- 16. Chan MH, Wong VW, Wong CK, Chan PK, Chu CM, Hui DS, et al. Serum LD1
- isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute
- 607 respiratory syndrome. J Intern Med. 2004;255(4):512-518.

- 17. Su R, Li Z, Wang Y, Liu Y, Zheng X, Gao C, et al. Imbalance between Th17 and
- 609 regulatory T cells in patients with systemic lupus erythematosus combined
- 610 EBV/CMV viraemia. Clin Exp Rheumatol. 2019. PMID: 31820723
- 611 18. Cheng Y, Zhao H, Song P, Zhang Z, Chen J, Zhou YH. Dynamic changes of
- 612 lymphocyte counts in adult patients with severe pandemic H1N1 influenza A. J Infect
- 613 Public Health. 2019;12(6):878-883.
- 19. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2
- receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci.
- 616 2020;12(1):8.
- 617 20. Ko JH, Park GE, Lee JY, Lee JY, Cho SY, Ha YE, et al. Predictive factors for
- pneumonia development and progression to respiratory failure in MERS-CoV
  infected patients. J Infect. 2016;73(5):468-475.
- 21. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2
- 621 infection-a review of immune changes in patients with viral pneumonia. Emerg622 Microbes Infect. 2020;9(1):727-732.
- 623 22. Sant AJ, McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J
- 624 Exp Med. 2012;209(8):1391-1395.
- 23. He Z, Zhao C, Dong Q, Zhuang H, Song S, Peng G, et al. Effects of severe acute
- respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes
- and their subsets. Int J Infect Dis. 2005;9(6):323-330.
- 628 24. Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective.
- 629 Expert Opin Pharmacother. 2001;2(10):1671-1683.
- 630 25. O'Sullivan TE, Sun JC, Lanier LL. Natural Killer Cell Memory. Immunity.
- 631 2015;43(4):634-645.

632	26. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection:
633	the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454.
634	
635	
636	
637	
638	
639	
640	
641	
642	
643	
644	
645	
646	
647	
648	
649	
650	
651	
652	

Characteristics	Healthy	althy Non-severeSevere		Severe influenza					
	Donors	COVID-19	COVID-19	А					
	n=110	n=80	n=19	n=43					
Age groups (years), me	dian45(34, 65)	37(30, 49)	67(53, 74)	70(64,83)					
(IQR)									
Gender N,(%)									
Male	53 (48.0)	41	15 (79.0)	30 (70.0)					
		(51.0)							
Female	57 (52.0)	39	4 (21.0)	13 (30.0)					
		(49.0)							
Admission time, me	dian/	4 (2, 7)	5 (4.5, 10)	3 (2, 5)					
(IQR)									
Common Symptoms N,(9	%)								
Fever	/	58	19 (100.0)	43 (100.0)					
		(73.0)							
Cough	/	38	19 (100.0)	43 (100.0)					
		(48.0)							
Dyspnea	/	0	19 (100.0)	33(77.0)					
Co-existing complicat	ions								
N,(%)									
Other	/	19 (24.0)	12 (63.0)	36 (84.0)					

Table 1. Demographic and clinical characteristics of different study group	ps
--	----

Hypertension	/	16	8 (42.0)	28 (65.0)
		(20.0)		
Diabetes	/	4 (5.0)	4 (21.0)	11 (26.0)
COPD	/	1 (1.0)	1 (5.0)	9 (21.0)
Cardiovascular disease	/	0	2 (11.0)	17 (40.0)
Renal disease	/	0	1 (5.0)	3 (7.0)
Autoimmune disorders	/	2 (3.0)	3 (16.0)	1 (2.0)
Outcome N,(%)				
Survival	/	80 (100.0)	18 (95.0)	39 (91.0)
Deaths	/	0	1 (5.0)	4 (9.0)

Abbreviations: COPD: Chronic obstructive pulmonary disease; IQR: Interquartile range

Table 2. Summary of comparison of cell counts of total WBCs, total lymphocytes,

and lymphocyte subsets in patients with non-severe COVID-19, severe COVID-19,

	I II		III		IV			P value		
Daramatars	Healthy	Non-	Course		Severe					
randiteters		severe	COV		influenza	I-II	I-III	I-IV	II-III	III-IV
	Donors	COVID-19	COV	ID-19	А					
WBC(*10 <sup>9</sup> /L),	6.01	5 34 (4 11	3.92	(3 30	5.99					
Modian (IOP)	(5.02,	6 10)	4.21)		(4.08,	0.001	<0.0001	0.974	0.049	0.027
Meulan (IQK)	6.70)	0.10)			8.10)					
LY(*10 <sup>9</sup> /L)	1.78	1 51 (1 12		12 0.02 (0.72						
, median	(1.52,	1.83)	1.07)	(0.75,	(0.57,	0.027	< 0.0001	< 0.0001	< 0.0001	0.528
(IQR)	2.16)	1.03)	1.07)		1.24)					
NK cell count	271	102 (1/3	77	(57						
(cells/mm <sup>3</sup> ),	(151,	361)	283)	(37,	_	0.514	0.355	_	0.346	_
median (IQR)	397)	501)	203)							
B cell count		202 (150	1 47	(00						
(cells/mm <sup>3</sup> ),	_	203 (150,	14/	(89,	_	_	_	-	0.093	_
median (IQR)		299)	101)							
T cell count	1293	1199 (907,	461	(429,	550	0.00	0.001		0.000	0 (
(cells/mm <sup>3</sup> ).	(1121,	1521)	473)		(373,	0.096	0.001	< 0.0001	< 0.0001	0.452

and severe influenza A with the first week of illness.

median (IQR)	1641)					749)					
CD4+ count	669	690	(497	200	(247	283					
(cells/mm <sup>3</sup> ),	(557,	080	(482,	200	(247,	(180,	0.116	0.001	< 0.0001	0.001	0.686
median (IQR)	891)	017)		514)		418)					
CD8+ count	556	401	(261	1 4 4	/111	201					
(cells/mm <sup>3</sup> ),	(415,	421 701)	(301,	144	(111,	(149,	0.036	0.001	< 0.0001	0.001	0.163
median (IQR)	763)	701)		102)		303)					
CD4+/CD8+	1.23	1 57	(1.02	2.15	(1 45	1.37					
ratio, median	(0.97,	1.37	(1.02,	2.13	(1.45,	(1.01,	0.242	0.221	0.651	0.255	0.285
(IQR)	1.8)	1.00)	,	5.42)		1.97)					

Abbreviations: WBC: White blood cells, LY: Lymphocytes, IQR: Interquartile range;

P < 0.05 is statistically significant

## **Figure Legends**

**Fig. 1**. Dynamic variations in cell counts of total WBCs, total lymphocytes, and lymphocyte subsets in patients with non-severe COVID-19, severe COVID-19, and severe influenza A at weeks (W) 1, 2, 3, and 4 during the course of illness.

(A–B) Box plots illustrating percentages of total WBCs and total lymphocytes in different groups at different times. Kruskal–Wallis test followed by Dunn's multiple comparisons test or one-way analysis of variance (ANOVA) test followed by Tukey's multiple comparisons test was performed to determine significant differences between the groups. (C–H) Box plots illustrating total cell counts of lymphocyte subsets in different groups at different times. Spearman's nonparametric test was used to test for correlations. \*\* P<0.01, \*\*\* P<0.001 were considered significant.

# HD No severe COVID-19 Severe COVID-19 Severe Influenza A

В

Α





\* \*\*\* \*\*

 $\widehat{}$ 

\*









Н

